WHO Issues Concern Over Acute Shortage of Weight-Loss Jabs

Less than 10% of people that would benefit from obesity jabs including Wegovy can access them, states the World Health Organization as it releases its first recommendations on the drugs.

Given more than one billion individuals worldwide currently classified as obese, it is calling for increased and just availability to these injectable treatments.

Based on projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.

"Our new guidelines recognises that excess weight is a chronic disease that can be managed with comprehensive and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and logistical bottlenecks are key obstacles to broad availability to the jabs that can aid individuals in losing considerable weight, says the body.

Skinny Jab Shortage

Even under the present most optimistic scenario, the production of GLP-1 therapies would only suffice for around 100 million people – under 10% of the global need, per the health organization.

The recommendation encourages countries and companies to expand access, via strategies including patent sharing.

The intellectual property rights on semaglutide – the core ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.

The Way Obesity Drugs Operate

GLP-1 drugs replicate a body's own hormone to slow digestion, suppress the appetite and increase satiety so individuals consume fewer calories.

People commonly start to lose weight in the initial weeks of commencing the regular doses.

Research suggests users may see weight return within a year of halting the drug, because their typical food cravings resume.

To be overweight or obese raises your risk for developing diseases, such as diabetes, heart disease, stroke, and specific cancers.

Obesity concerns people in countries worldwide and was associated with millions of fatalities worldwide in 2024, per the WHO.